Biosensors International Appoints R. Chato Abad as Chief Financial Officer

Dec 01, 2005, 00:00 ET from Biosensors International Group, Ltd.

    NEWPORT BEACH, Calif., Dec. 1 /Xinhua-PRNewswire-FirstCall/ -- Biosensors
 International Group, Ltd. (''Biosensors'' or ''the Company''; Bloomberg: BIG
 SP), a developer, manufacturer and marketer of innovative medical devices for
 interventional cardiology and critical care procedures, today named Ms. R.
 Chato Abad as its new Chief Financial Officer, effective immediately.  Ms.
 Abad, who is based in the Company's office in Newport Beach, California,
 brings to Biosensors more than 15 years of senior financial management
 experience in the pharmaceutical and medical device industries.
     Prior to joining Biosensors, Ms. Abad acted as interim Chief Financial
 Officer at the US Generics Division of Alpharma, Inc., a multi-national
 manufacturer of branded and generic pharmaceuticals with sales in excess of
 US$450 million.  At Alpharma, she was closely involved in the successful sale
 of the US Generics Division to Actavis.  Previously, she spent more than 10
 years at Watson Pharmaceuticals, Inc. headquartered in Corona, California
 where she was the Vice President of Finance, and had responsibility for all
 financial, accounting and treasury functions as well as strategic planning.
 While at Watson, Ms. Abad was a key member of the management team that led
 Watson to its successful initial and secondary public offerings on the New
 York Stock Exchange.  During her tenure, Ms. Abad was also instrumental in
 directing the financial functions of Watson through its accelerated growth
 from sales revenue of US$1 million to US$1.2 billion.  Prior to her experience
 at Watson, Ms. Abad led the accounting function for a US$200 million division
 of a multinational manufacturer of ocular medical devices.
     ''With more than a decade of exceptional financial experience in a
 dynamically growing company like Watson, Chato certainly brings with her a
 wealth of experience that will be very valuable to Biosensors, said Mr.
 Yoh-Chie Lu, Chairman and CEO of Biosensors.  ''I am confident that Chato can
 provide Biosensors with strong financial leadership and will be instrumental
 in the next phase of the Company's growth to create additional value for our
     Ms. Abad received her bachelor of science in business administration
 degree from the College of the Holy Spirit, Philippines and holds an MBA from
 St. John's University, New York where she also received the Most Outstanding
 Scholastic Achievement Award in the field of accounting.
     About Biosensors International Group, Ltd.
     Biosensors develops, manufactures and markets innovative medical devices
 used in interventional cardiology and critical care procedures.  Biosensors is
 well-positioned to emerge as a leader in drug-eluting stents, an evolving
 therapy that is rapidly gaining market share from traditional therapies such
 as bare-metal stenting and open-heart surgery.  Biosensors has internally
 developed technology to address each component of a drug-eluting stent system,
 including a stent, a stent delivery catheter, a bioresorbable polymer and a
 proprietary anti-restenotic drug.  It is pursuing two separate drug-eluting
 stent programs, BioMatrix(TM) and Axxion(TM), and has licensed aspects of its
 drug-eluting stent technology to four companies.
     Forward Looking Statements
     Certain statements herein include forward-looking statements within the
 meaning of the U.S. Private Securities Litigation Reform Act of 1995.
 Forward-looking statements generally can be identified by the use of
 forward-looking terminology, such as "may," "will," "expect," "intend,"
 ''estimate,'' ''anticipate,'' ''believe,'' ''project'' or ''continue'' or the
 negative thereof or other similar words.  All forward-looking statements
 involve risks and uncertainties, including, but not limited to, customer
 acceptance and market share gains, competition from companies that have
 greater financial resources; introduction of new products into the marketplace
 by competitors; successful product development; dependence on significant
 customers; the ability to recruit and retain quality employees as Biosensors
 grows; and economic and political conditions globally.  Actual results may
 differ materially from those discussed in, or implied by, the forward-looking
 statements.  The forward-looking statements speak only as of the date of this
 release and Biosensors assumes no duty to update them to reflect new, changing
 or unanticipated events or circumstances.
     Media Contact Information
     Biosensors International Group
      Ms Tina Lim, Executive, Corporate Communications
      Tel:   +65-6213-5712
     Media Relations / Investor Relations Firms
     WeR1 Consultants Pte Ltd
      Ms. Mona Leong
      Senior Consultant
      Tel:   +65-6737-4844 / Hp: +65-9187-4449
     United States
     Allen & Caron Inc.
      Mr. Matt Clawson
      Executive Vice President, Investor Relations
      Tel:  +1-949-474-4300

SOURCE Biosensors International Group, Ltd.